TSX Venture: QPT
EDMONTON, Nov. 1, 2011 /PRNewswire/ - Quest PharmaTech Inc.
(TSXV: QPT) ("Quest" or the "Company"), a pharmaceutical company
developing and commercializing products for the treatment of
cancer, today announced that it will be making a presentation at
the 2nd Biennial Meeting of the Asian Society of
Gynecologic Oncology, in Seoul, South
Korea, November 3-5. The
presentation, entitled "Targeting Dendritic Cells to Create a More
Powerful Immune Response: A New Approach for the Immunotherapy of
Ovarian Cancer using anti-CA125 MAb, Oregovomab", will be presented
by Dr. Chris Nicodemus, Chief
Scientific Officer of Advanced Immune Therapeutics and Chairman of
Quest's Clinical Advisory Board. Dr. Jonathan S. Berek, Professor and Director,
Stanford Women's Cancer Center,
Stanford Cancer Institute, Stanford
University School of Medicine, and Chair, Cooperative
Ovarian Cancer Group, Stanford,
California , is one of the co-authors of this presentation,
along with Dr. Madi R. Madiyalakan,
CEO of Quest. Dr. Berek has also been invited to make a
presentation on 'Genetics of Ovarian Cancer' during the
conference.
The Company's presentation will highlight its
clinical experience with the immunotherapy of ovarian cancer using
oregovomab, its unique mechanism in targeting dendritic cells to
activate cytotoxic T cell responses, and the Company's strategy of
using combinatorial therapies (chemotherapy and/or
immuno-adjuvants) to better mobilize anti-tumor immunity. Dendritic
cell based immunotherapeutic strategies are gaining momentum in
recent days, especially after the award of this year's Noble Prize
in Medicine for the discovery of the central role of dendritic
cells in mobilizing the adaptive immune system.
"With a large shareholder base in South Korea, this is an excellent opportunity
for Quest to present to the Asian gynecologic oncology community
our unique approach for immunotherapy of ovarian cancer", said Dr.
Madiyalakan, who will also be attending the ASGO conference.
The Company is in the process of translating its
valuable intellectual property into commercial success by
conducting three carefully planned proof-of-concept clinical trials
to establish the superiority of combinatorial immunotherapy either
with front-line chemotherapy consisting of carboplatin/paclitaxel
in ovarian cancer, gemcitabine in pancreatic cancer, or with the
addition of an immunoadjuvant. The Company hopes that successful
results from these studies will lead to the design of a definitive
product registration study.
About Quest PharmaTech Inc.
Quest is a publicly traded, Alberta-based biotechnology company committed
to the development and commercialization of oncology product
candidates. It is developing a series of products for the treatment
of cancer based on its pipeline of SonoLight compounds, and
monoclonal antibodies that target certain tumor antigens that are
presented in a variety of cancers. Quest believes that by combining
these antibodies with other cancer therapies such as chemotherapy
or photodynamic therapy, it can potentially further complement and
enhance treatment outcomes compared to antibody treatment
alone.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Quest PharmaTech Inc.